Holen Sie sich die Stockscreener-App
133.05
1.40%
-1.89
Handel nachbörslich:
132.05
-1.00
-0.75%
Überblick
Nachrichten
Preisverlauf
Optionskette
Financials
Warum fällt GILD?
Forum
Prognose
Aktiensplit
Dividendenhistorie
Schlusskurs vom Vortag:
$134.94
Offen:
$133.552
24-Stunden-Volumen:
6.66M
Relative Volume:
1.05
Marktkapitalisierung:
$165.19B
Einnahmen:
$29.79B
Nettoeinkommen (Verlust:
$9.22B
KGV:
18.10
EPS:
7.3494
Netto-Cashflow:
$10.23B
1W Leistung:
-2.38%
1M Leistung:
-4.30%
6M Leistung:
+6.27%
1J Leistung:
+31.17%
1-Tages-Spanne:
$131.88
$135.07
1-Wochen-Bereich:
$129.00
$137.50
52-Wochen-Spanne:
$97.86
$157.29
Gilead Sciences Inc Stock (GILD) Company Profile
Firmenname
Gilead Sciences Inc
Sektor
Telefon
(650) 574-3000
Adresse
333 LAKESIDE DR, FOSTER CITY, CA
Compare GILD vs LLY, JNJ, ABBV, AZN, NVS
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
GILD
Gilead Sciences Inc
|
133.05 | 167.54B | 29.79B | 9.22B | 10.23B | 7.3494 |
LLY
Lilly Eli Co
|
1,015.75 | 882.71B | 72.25B | 25.28B | 10.37B | 27.78 |
JNJ
Johnson Johnson
|
230.42 | 539.84B | 96.36B | 21.04B | 17.80B | 8.6488 |
ABBV
Abbvie Inc
|
208.50 | 367.25B | 62.82B | 3.60B | 19.98B | 2.0274 |
AZN
Astrazeneca Plc
|
187.72 | 286.19B | 60.48B | 10.40B | 8.05B | 3.3297 |
NVS
Novartis Ag Adr
|
149.75 | 282.70B | 54.66B | 13.58B | 16.05B | 7.0171 |
Gilead Sciences Inc Stock (GILD) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2026-03-10 | Eingeleitet | Jefferies | Buy |
| 2026-02-20 | Eingeleitet | Barclays | Equal Weight |
| 2026-02-11 | Bestätigt | Needham | Buy |
| 2026-01-07 | Fortgesetzt | UBS | Buy |
| 2025-11-24 | Fortgesetzt | Truist | Buy |
| 2025-11-13 | Eingeleitet | Scotiabank | Sector Outperform |
| 2025-08-19 | Hochstufung | Daiwa Securities | Neutral → Outperform |
| 2025-08-08 | Hochstufung | Truist | Hold → Buy |
| 2025-07-25 | Hochstufung | Needham | Hold → Buy |
| 2025-04-22 | Fortgesetzt | Cantor Fitzgerald | Overweight |
| 2025-03-04 | Bestätigt | Oppenheimer | Outperform |
| 2025-02-18 | Hochstufung | Deutsche Bank | Hold → Buy |
| 2025-02-13 | Hochstufung | DZ Bank | Hold → Buy |
| 2025-01-10 | Hochstufung | Morgan Stanley | Equal-Weight → Overweight |
| 2024-12-10 | Fortgesetzt | BofA Securities | Buy |
| 2024-11-15 | Eingeleitet | Wolfe Research | Outperform |
| 2024-11-14 | Eingeleitet | Citigroup | Buy |
| 2024-11-08 | Herabstufung | Maxim Group | Buy → Hold |
| 2024-10-21 | Hochstufung | Leerink Partners | Market Perform → Outperform |
| 2024-10-17 | Eingeleitet | Bernstein | Outperform |
| 2024-10-07 | Hochstufung | Wells Fargo | Equal Weight → Overweight |
| 2024-07-08 | Hochstufung | Raymond James | Mkt Perform → Outperform |
| 2024-05-01 | Bestätigt | Maxim Group | Buy |
| 2024-04-24 | Hochstufung | HSBC Securities | Reduce → Hold |
| 2024-02-22 | Herabstufung | Truist | Buy → Hold |
| 2023-11-09 | Eingeleitet | Deutsche Bank | Hold |
| 2023-09-08 | Hochstufung | BofA Securities | Neutral → Buy |
| 2023-09-06 | Eingeleitet | HSBC Securities | Reduce |
| 2023-07-24 | Bestätigt | Barclays | Equal Weight |
| 2023-05-16 | Hochstufung | BMO Capital Markets | Market Perform → Outperform |
| 2023-04-28 | Fortgesetzt | Piper Sandler | Overweight |
| 2023-01-03 | Herabstufung | RBC Capital Mkts | Outperform → Sector Perform |
| 2022-12-13 | Fortgesetzt | BofA Securities | Neutral |
| 2022-12-09 | Herabstufung | DZ Bank | Buy → Hold |
| 2022-10-31 | Hochstufung | Barclays | Underweight → Equal Weight |
| 2022-10-28 | Bestätigt | BMO Capital Markets | Market Perform |
| 2022-10-28 | Bestätigt | Cowen | Outperform |
| 2022-10-28 | Bestätigt | JP Morgan | Overweight |
| 2022-10-28 | Bestätigt | Jefferies | Buy |
| 2022-10-28 | Hochstufung | Piper Sandler | Neutral → Overweight |
| 2022-10-28 | Bestätigt | RBC Capital Mkts | Outperform |
| 2022-10-28 | Hochstufung | Truist | Hold → Buy |
| 2022-10-28 | Bestätigt | Wells Fargo | Equal Weight |
| 2022-10-04 | Hochstufung | JP Morgan | Neutral → Overweight |
| 2022-07-13 | Eingeleitet | Cantor Fitzgerald | Neutral |
| 2022-05-23 | Eingeleitet | SVB Leerink | Mkt Perform |
| 2022-02-28 | Herabstufung | BMO Capital Markets | Outperform → Market Perform |
| 2022-02-02 | Bestätigt | BMO Capital Markets | Outperform |
| 2022-02-02 | Bestätigt | BofA Securities | Neutral |
| 2022-02-02 | Bestätigt | RBC Capital Mkts | Outperform |
| 2022-02-02 | Bestätigt | Truist | Hold |
| 2022-02-02 | Bestätigt | Wells Fargo | Equal Weight |
| 2022-01-28 | Hochstufung | Argus | Hold → Buy |
| 2022-01-06 | Herabstufung | Morgan Stanley | Overweight → Equal-Weight |
| 2021-12-09 | Fortgesetzt | Wells Fargo | Equal Weight |
| 2021-12-06 | Eingeleitet | Goldman | Neutral |
| 2021-11-19 | Hochstufung | BMO Capital Markets | Market Perform → Outperform |
| 2021-11-19 | Fortgesetzt | Piper Sandler | Neutral |
| 2021-10-20 | Fortgesetzt | Cowen | Outperform |
| 2021-07-30 | Bestätigt | BMO Capital Markets | Market Perform |
| 2021-07-30 | Bestätigt | RBC Capital Mkts | Outperform |
| 2021-04-01 | Hochstufung | Bernstein | Mkt Perform → Outperform |
| 2021-03-30 | Hochstufung | Redburn | Neutral → Buy |
| 2021-01-19 | Hochstufung | Morgan Stanley | Equal-Weight → Overweight |
| 2021-01-04 | Hochstufung | Guggenheim | Neutral → Buy |
| 2020-11-03 | Fortgesetzt | Morgan Stanley | Equal-Weight |
| 2020-10-28 | Eingeleitet | UBS | Neutral |
| 2020-09-30 | Fortgesetzt | Jefferies | Buy |
| 2020-09-15 | Hochstufung | Maxim Group | Hold → Buy |
| 2020-07-31 | Bestätigt | Credit Suisse | Neutral |
| 2020-07-31 | Bestätigt | Morgan Stanley | Equal-Weight |
| 2020-07-31 | Bestätigt | Piper Sandler | Overweight |
| 2020-07-31 | Bestätigt | RBC Capital Mkts | Outperform |
| 2020-07-31 | Bestätigt | SunTrust | Hold |
| 2020-07-31 | Bestätigt | Wells Fargo | Equal Weight |
| 2020-07-20 | Hochstufung | Credit Suisse | Underperform → Neutral |
| 2020-06-03 | Hochstufung | SVB Leerink | Mkt Perform → Outperform |
| 2020-05-26 | Hochstufung | SunTrust | Sell → Hold |
| 2020-05-01 | Herabstufung | JP Morgan | Overweight → Neutral |
| 2020-05-01 | Herabstufung | Raymond James | Outperform → Mkt Perform |
| 2020-05-01 | Herabstufung | SunTrust | Hold → Sell |
| 2020-04-27 | Herabstufung | UBS | Buy → Neutral |
| 2020-04-20 | Herabstufung | BMO Capital Markets | Outperform → Market Perform |
| 2020-04-20 | Herabstufung | Wells Fargo | Overweight → Equal Weight |
| 2020-04-17 | Herabstufung | CFRA | Hold → Sell |
Alle ansehen
Gilead Sciences Inc Aktie (GILD) Neueste Nachrichten
Gilead to Present New Data Advancing Care in PBC and Viral Hepatitis at EASL 2026 - BioSpace
Gilead’s Transition Into A Long-Duration Biotech Platform (NASDAQ:GILD) - Seeking Alpha
Gilead to present liver disease data at EASL conference By Investing.com - Investing.com Canada
Gilead Sciences, Inc. $GILD Shares Sold by VIRGINIA RETIREMENT SYSTEMS ET Al - MarketBeat
Nurix Therapeutics to Participate in Upcoming Investor Conferences - GlobeNewswire Inc.
Trek Financial LLC Purchases 13,041 Shares of Gilead Sciences, Inc. $GILD - MarketBeat
RBC Capital Remains a Hold on Gilead Sciences (GILD) - The Globe and Mail
Bailard Inc. Has $90.10 Million Holdings in Gilead Sciences, Inc. $GILD - MarketBeat
GILD Q1 Deep Dive: HIV Growth, Oncology Pipeline, and Margin Management Shape 2026 Outlook - Yahoo Finance
Gilead Sciences, Inc. (GILD) Outlook Cut Sharply on $11.5B IPR&D and Financing Costs - Insider Monkey
Gilead Sciences (NASDAQ:GILD) Price Target Lowered to $167.00 at Rothschild & Co Redburn - MarketBeat
RBC Capital maintains Gilead Sciences stock rating on UC drug data - Investing.com Canada
Gilead Sciences stock (US3755581036): Biotech leader navigates HIV and oncology markets - AD HOC NEWS
Gilead Sciences, Inc. (NASDAQ:GILD) Just Released Its First-Quarter Results And Analysts Are Updating Their Estimates - Yahoo Finance
Swiss Life Asset Management Ltd Reduces Holdings in Gilead Sciences, Inc. $GILD - MarketBeat
Gilead Reports Strong HIV Growth, Raises Outlook for 2026 - Value The Markets
Kepler Cheuvreux Suisse SA Acquires New Position in Gilead Sciences, Inc. $GILD - MarketBeat
Securian Asset Management Inc. Has $4.14 Million Holdings in Gilead Sciences, Inc. $GILD - MarketBeat
Gilead Sciences, Inc. $GILD Shares Acquired by ABN AMRO Bank N.V. - MarketBeat
NewEdge Wealth LLC Grows Holdings in Gilead Sciences, Inc. $GILD - MarketBeat
JSF Financial LLC Takes $1.25 Million Position in Gilead Sciences, Inc. $GILD - MarketBeat
Stronger HIV Pipeline And Acquisition Charges Might Change The Case For Investing In Gilead Sciences (GILD) - Yahoo Finance
Leerink Partners Lowers Gilead Sciences (NASDAQ:GILD) Price Target to $146.00 - MarketBeat
A Quick Look at Today's Ratings for Gilead Sciences(GILD.US), With a Forecast Between $157 to $177 - Moomoo
Manning & Napier Advisors LLC Has $13.39 Million Holdings in Gilead Sciences, Inc. $GILD - MarketBeat
Gilead Sciences stock (US3755581036): Biotech giant eyes growth in HIV and oncology markets - AD HOC NEWS
Crossmark Global Holdings Inc. Buys 23,719 Shares of Gilead Sciences, Inc. $GILD - MarketBeat
Gilead Sciences Is Maintained at Sector Perform by RBC Capital - Moomoo
Gilead Sciences (NASDAQ:GILD) Stock Rating Lowered by Wall Street Zen - MarketBeat
Research Alert: We Keep Our Buy Rating On Shares Of Gilead Sciences, Inc. - Moomoo
Gilead Sciences (GILD) Form 13F lists $2.12B holdings across 6 positions - Stock Titan
Gilead Sciences Price Target Raised to $157.00/Share From $155.00 by Truist Securities - Moomoo
Gilead Sciences Faces Long-Term Questions on Yeztugo Growth, RBC Capital Markets Says - Moomoo
Scotiabank Maintains Gilead Sciences(GILD.US) With Buy Rating, Maintains Target Price $177 - Moomoo
[Press release] FDA grants priority review of New Drug Application for Gilead’s once-daily HIV treatment of bictegravir plus lenacapavir - European AIDS Treatment Group
Truist Financial Reaffirms "Buy" Rating for Gilead Sciences (NASDAQ:GILD) - MarketBeat
Gilead Sciences’ Q1 Boosted by Biktarvy Growth and Yeztugo Launch - geneonline.com
Gilead Sciences (NASDAQ:GILD) Price Target Cut to $122.00 by Analysts at Royal Bank Of Canada - MarketBeat
Gilead posts positive Q1 buoyed by HIV drug growth - Pharmaceutical Technology
Following Major Q1 Acquisitions, Gilead Readjusts Year-End Guidance - Precision Medicine Online
Leerink Partners Adjusts Price Target on Gilead Sciences to $146 From $148 - marketscreener.com
Gilead cranks up Yeztugo first-year sales forecast to $1B on 'unprecedented launch trajectory' - Fierce Pharma
Morgan Stanley Adjusts Price Target on Gilead Sciences to $168 From $175 - Moomoo
Lilly, Gilead lead pharma’s M&A boom - BioPharma Dive
GILD Beats Q1 Earnings and Sales Estimates, Lowers '26 EPS View - TradingView
How A Surprise Player Stole The Show In Gilead's First Quarter - Investor's Business Daily
Needham Maintains Gilead Sciences(GILD.US) With Buy Rating, Maintains Target Price $170 - Moomoo
Gilead Sciences, Inc. (NASDAQ:GILD) Plans Quarterly Dividend of $0.82 - MarketBeat
Gilead Sciences (GILD) Announces Quarterly Dividend and Adjusts 2026 Outlook - GuruFocus
Gilead (GILD) Q1 2026 Earnings Call Transcript - The Globe and Mail
Gilead Sciences (GILD) Stock Drops Despite Q1 Beat on Massive Acquisition Charges - MEXC
Finanzdaten der Gilead Sciences Inc-Aktie (GILD)
Umsatz
Nettogewinn
Free Cashflow
ENV
0.05%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):